ERBB2 and breast cancer: To further investigate the prognostic implications of CNVs in the migratory SC-f tumor subtype, we tested the EGFR (7p11.2) gains with a migratory tumor signature in HR+/HER2-BC using the TCGA-BRCA (Figure 3e).